Parsaclisib
Parsaclisib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 8 | 9 | 1 | — | — | 15 |
| Follicular lymphoma | D008224 | — | C82 | 3 | 3 | 1 | — | — | 7 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | — | 2 | 1 | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | 2 | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | — | 1 | — | — | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | 1 | 1 | — | — | 2 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | — | 1 | 1 | — | — | 2 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | 1 | — | — | 2 |
| Hemolysis | D006461 | — | — | — | 1 | 1 | — | — | 2 |
| Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | — | 1 | 1 | — | — | 2 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 7 | 3 | — | — | — | 8 |
| B-cell lymphoma | D016393 | — | — | 4 | 3 | — | — | — | 6 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 3 | — | — | — | 5 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 2 | — | — | — | 4 |
| T-cell lymphoma | D016399 | — | — | 2 | 1 | — | — | — | 2 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 1 | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 1 | — | — | — | 1 |
| Pemphigus | D010392 | EFO_1000749 | L10 | — | 1 | — | — | — | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Parsaclisib |
| INN | parsaclisib |
| Description | Parsaclisib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. |
| Classification | Small molecule |
| Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 1426698-88-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297615 |
| ChEBI ID | — |
| PubChem CID | 86677874 |
| DrugBank | DB14867 |
| UNII ID | OS7097575K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PIK3CD
PIK3CD
Organism
Homo sapiens
Gene name
PIK3CD
Gene synonyms
NCBI Gene ID
Protein name
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Protein synonyms
p110delta, Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta short variant 8/20, phosphoinositide-3-kinase C, phosphoinositide-3-kinase, catalytic, delta polypeptide variant p37delta, PI3-kinase p110 subunit delta, PI3Kdelta, PtdIns-3-kinase subunit p110-delta
Uniprot ID
Mouse ortholog
Pik3cd (18707)
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Q8CJ28)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 315 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
79 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use